Replies to post #374286 on Anavex Life Sciences Corp (AVXL)

[JWC3]

Nothing!

[JWC3]

Perhaps we are seeing buyout paranoia on the part of Missling? He wants to get data from all 3 sets of trials to be simultaneously evaluated by the FDA so the MC of AVXL appreciates instantaneously for AD, PD, PDD, RETTS. That would insure we get buyout offers at a maximal price!

[Steady_T]

It was a Parkinson's Dementia trial. The motor improvements were a secondary endpoint. It was a P2 trial with moderate n of 132.

Still, the published results so far were pretty good. Theoretically Anavex is waiting on guidance from the FDA on proceeding with a P3 and PD trial guidance.

[RedShoulder]

Can someone tell me what was bad about the parkinsons trial?

I mean parkinsons alone should be enough for us to be at 50 dollars. I don’t know any other drugs that improve motor symptoms. Most just suppress tremors

peeved as we all know 92% of the high dose improved, no Parkinson drug has ever achieved that, not even close.

I see no obstacles as A2-73 Blarcamesine is approved for both PD and PDD.

I have more faith that PD/PDD will become approved and the WW SOC than any other condition because the evidence of the results are overwhelmingly positive. That said, I believe AD and Rett will be the approved SOC too.
----------------------clip--------------------------------
"Global Parkinson’s Disease Therapeutics Market $10.5 Billion by 2029
September 9, 2022 by iHealthcareAnalyst, Inc."

The global market for Parkinson’s disease therapeutics estimated to reach $10.5 billion by 2029, expanding at a CAGR of 12.5% over the forecast period, driven by aging population, drug price inflation, and introduction of new treatment options.

Parkinson’s disease (PD) is the second most common neurodegenerative disorder following Alzheimer’s disease worldwide, affecting 2–3?% of the population?≥?65 years of age. Parkinson’s disease currently affects 13 million people worldwide and, due to an aging population, is estimated to affect 32 million by 2050. Men are 1.5 times more likely to have Parkinson’s than women.

An estimated 4 percent of people with Parkinson’s are diagnosed before age 50. The incidence of Parkinson’s disease is linked to risk and protective factors such as industrial chemicals and pollutants, such as pesticides, solvents, and metals.

https://www.ihealthcareanalyst.com/global-parkinsons-disease-therapeutics-market/
----------------------end clip--------------------------
What I don't understand why the PDD/PD high dose data did not move the SP, it is pretty much a 'freebee' you get buying this stock for AD and Rett.

Yet it is a multi-Billion PD market waiting for a drug that works to improve the condition. Maybe the OLE data will light a fire if it shows that they kept improving.

This ultra low SP does not reflect the potential revenue with data like the PDD/PD Ph-2 trial, Rett Avatar, and what Is highly likely to be a successful AD TLDR.